相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety, Tolerability, and Pharmacokinetics of Multiple Repeated Oral Doses of the α2/3/5-Subtype Selective GABAA-Positive Allosteric Modulator PF-06372865 in Healthy Volunteers
Rachel Gurrell et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2021)
230 days of ultra long-term subcutaneous EEG: seizure cycle analysis and comparison to patient diary
Pedro F. Viana et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)
The 5th International Lafora Epilepsy Workshop: Basic science elucidating therapeutic options and preparing for therapies in the clinic
Matthew S. Gentry et al.
EPILEPSY & BEHAVIOR (2020)
Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial
Gregory L. Krauss et al.
LANCET NEUROLOGY (2020)
Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study
Michael R. Sperling et al.
EPILEPSIA (2020)
Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures
Steve S. Chung et al.
NEUROLOGY (2020)
Drug-Responsive Inhomogeneous Cortical Modulation by Direct Current Stimulation
Yan Sun et al.
ANNALS OF NEUROLOGY (2020)
Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression
Kian Huat Lim et al.
NATURE COMMUNICATIONS (2020)
Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome
Zhou Han et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multi-centre, double-blind, randomised, placebo-controlled, dose-response trial (vol 19, pg 38, 2020)
G. L. Krauss et al.
LANCET NEUROLOGY (2020)
Photosensitive epilepsy Robust clinical efficacy of a selective GABA potentiator
Rachel Gurrell et al.
NEUROLOGY (2019)
Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study
Afshin Saffari et al.
ORPHANET JOURNAL OF RARE DISEASES (2019)
Targeting Pathogenic Lafora Bodies in Lafora Disease Using an Antibody-Enzyme Fusion
M. Kathryn Brewer et al.
CELL METABOLISM (2019)
Inhaled alprazolam rapidly suppresses epileptic activity in photosensitive participants
Jacqueline A. French et al.
EPILEPSIA (2019)
Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons
Michiko Nakamura et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2019)
A novel rapamycin analog is highly selective for mTORC1 in vivo
Katherine H. Schreiber et al.
NATURE COMMUNICATIONS (2019)
TMS as a pharmacodynamic indicator of cortical activity of a novel anti-epileptic drug, XEN1101
Isabella Premoli et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2019)
Ultra-long-term subcutaneous home monitoring of epilepsy-490 days of EEG from nine patients
Sigge Weisdorf et al.
EPILEPSIA (2019)
Diazepam buccal film for the treatment of acute seizures
Michael A. Rogawski et al.
EPILEPSY & BEHAVIOR (2019)
Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes
Jeffrey W. Chen et al.
ANNALS OF PHARMACOTHERAPY (2019)
Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial
Lieven Lagae et al.
LANCET (2019)
The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet
Christine A. Olson et al.
CELL (2018)
The novel sodium channel modulator GS-458967 (GS967) is an effective treatment in a mouse model of SCN8A encephalopathy
Erin M. Baker et al.
EPILEPSIA (2018)
Potent and selective pharmacodynamic synergy between the metabotropic glutamate receptor subtype 2-positive allosteric modulator JNJ-46356479 and levetiracetam in the mouse 6-Hz (44-mA) model
Cameron S. Metcalf et al.
EPILEPSIA (2018)
Lafora disease - from pathogenesis to treatment strategies
Felix Nitschke et al.
NATURE REVIEWS NEUROLOGY (2018)
Valium without dependence? Individual GABAA receptor subtype contribution toward benzodiazepine addiction, tolerance, and therapeutic effects
Tianze Cheng et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2018)
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Orrin Devinsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Ganaxolone : A New Treatment for Neonatal Seizures
Tamara Yawno et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2017)
KCNQ2 encephalopathy Features, mutational hot spots, and ezogabine treatment of 11 patients
John J. Millichap et al.
NEUROLOGY-GENETICS (2016)
Allosteric modulation of sigma-1 receptors elicits anti-seizure activities
Lin Guo et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Pharmacokinetic and pharmacodynamic characterisation of JNJ-40411813, a positive allosteric modulator of mGluR2, in two randomised, double-blind phase-I studies
Hiba Salih et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
TMS- EEG Signatures of GABAergic Neurotransmission in the Human Cortex
Isabella Premoli et al.
JOURNAL OF NEUROSCIENCE (2014)
Inborn errors of creatine metabolism and epilepsy
Vincenzo Leuzzi et al.
EPILEPSIA (2013)
A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials
Michael Wong
EXPERT REVIEW OF NEUROTHERAPEUTICS (2013)
Prediction of seizure likelihood with a long-term, implanted seizure advisory system in patients with drug-resistant epilepsy: a first-in-man study
Mark J. Cook et al.
LANCET NEUROLOGY (2013)
Sodium channel SCN8A (Nav1.6): properties and de novo mutations in epileptic encephalopathy and intellectual disability
Janelle E. O'Brien et al.
Frontiers in Genetics (2013)
Design and Synthesis of Neuroprotective Methylthiazoles and Modification as NO-Chimeras for Neurodegenerative Therapy
Zhihui Qjn et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
σ-1 Receptor Agonist SKF10047 Inhibits Glutamate Release in Rat Cerebral Cortex Nerve Endings
Cheng-Wei Lu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
De novo SCN1A mutations in Dravet syndrome and related epileptic encephalopathies are largely of paternal origin
Sarah E. Heron et al.
JOURNAL OF MEDICAL GENETICS (2010)
Anticonvulsant and Antiepileptic Actions of 2-Deoxy-D-Glucose in Epilepsy Models
Carl E. Stafstrom et al.
ANNALS OF NEUROLOGY (2009)
Cholesterol 24-Hydroxylase: An Enzyme of Cholesterol Turnover in the Brain
David W. Russell et al.
ANNUAL REVIEW OF BIOCHEMISTRY (2009)
Differential contribution of GABAA receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands
Rosa L. Fradley et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2007)
2-deoxy-D-glucose reduces epilepsy progression by NRSF-CtBP-dependent metabolic regulation of chromatin structure
Mireia Garriga-Canut et al.
NATURE NEUROSCIENCE (2006)
The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via σ1 receptor activation:: comparison with the effects of dextromethorphan
EJ Shin et al.
BRITISH JOURNAL OF PHARMACOLOGY (2005)
分享论文
